1. Home
  2. OBDC vs GKOS Comparison

OBDC vs GKOS Comparison

Compare OBDC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Owl Capital Corporation

OBDC

Blue Owl Capital Corporation

HOLD

Current Price

$11.60

Market Cap

5.6B

Sector

Finance

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$118.07

Market Cap

6.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBDC
GKOS
Founded
2015
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.9B
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
OBDC
GKOS
Price
$11.60
$118.07
Analyst Decision
Buy
Strong Buy
Analyst Count
9
14
Target Price
$14.28
$133.07
AVG Volume (30 Days)
7.7M
705.7K
Earning Date
04-27-2026
05-14-2026
Dividend Yield
13.10%
N/A
EPS Growth
N/A
N/A
EPS
1.24
N/A
Revenue
N/A
$507,442,000.00
Revenue This Year
N/A
$23.29
Revenue Next Year
N/A
$27.74
P/E Ratio
$9.31
N/A
Revenue Growth
N/A
32.33
52 Week Low
$10.70
$73.16
52 Week High
$15.36
$130.23

Technical Indicators

Market Signals
Indicator
OBDC
GKOS
Relative Strength Index (RSI) 46.04 51.87
Support Level $11.15 $79.71
Resistance Level $14.67 $130.23
Average True Range (ATR) 0.44 5.31
MACD 0.03 0.44
Stochastic Oscillator 51.34 74.50

Price Performance

Historical Comparison
OBDC
GKOS

About OBDC Blue Owl Capital Corporation

Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: